Clinical Trials
28 trialsRADIAN
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Merus B.V.
FORTIFI-HN01
Bicara Therapeutics
INTERLINK-1
AstraZeneca
H&NRAD-2025-01
Humanitas University
Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer
Vanderbilt-Ingram Cancer Center
High-Resolution PET-CT Imaging for Surgical Margin Visualization
Vanderbilt-Ingram Cancer Center
Biospecimen Procurement for Head and Neck Disorders
National Institutes of Health Clinical Center (CC)
5-Fluorouracil Response and Optimization STudy (The FROST Trial)
Washington University School of Medicine
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
University of Pittsburgh
DEREDIA
Centre Oscar Lambret
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy for HPV + Oropharyngeal Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)
EMD Serono
CONFIRM
Brigham and Women's Hospital
AI System for Anatomic Recognition & Lesion Detection in Nasopharyngolaryngoscopy: A Prospective Study
Ruijin Hospital
The Objective is to Respond to Patients' Needs in the Field of Larynx Replacement
University Hospital, Strasbourg, France
TL&TPL
Fondazione IRCCS Policlinico San Matteo di Pavia
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology, LLC
G-FORCE
University of Texas Southwestern Medical Center
NIDCD Otolaryngology Clinical Protocol Biospecimen Bank
National Institutes of Health Clinical Center (CC)
Pembrolizumab in Combination With CRT for LA-SCCHN
Sanford Health
The Head and Neck Tumor Biobank
Maastricht Radiation Oncology
Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
EMD Serono
SALTORL
Groupe Oncologie Radiotherapie Tete et Cou
Assessment of Laryngopharyngeal Sensation: Cancer Survivor Cohort
University of California, San Francisco
Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
UNC Lineberger Comprehensive Cancer Center
Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck
Thomas Jefferson University